Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
• To evaluate the effect of nilotinib on pulmonary vascular resistance (PVR) compared to placebo after 24 weeks of therapy
Inclusion criteria
- Pulmonary Arterial Hypertension (PAH) Class II or III patients remaining symptomatic despite at least one PAH-specific therapy